At Kalypsys, we use our capabilities in drug discovery, medicinal chemistry and translational medicine to discover and develop high quality, small molecule medicines in timelines that are significantly faster than pharmaceutical industry norms. Our rapidly advancing pipeline is focused on three therapeutic areas that target some of the world's most widespread diseases: cardiovascular/metabolic diseases, pain/inflammation and oncology.
We currently have two compounds in clinical trials, (KD3010)(Phase Ib) and (KD7040) (Phase I to be initiated in 1Q07), and anticipate filing additional IND's in 2007. Each of our programs is supported by aggressive patent filings to ensure freedom to operate with Kalypsys compounds.
